Placebo for verinurad

DRUG2 trials

Sponsors

AstraZeneca

Conditions

Chronic Kidney DiseaseHeart Failure With Preserved Ejection Fraction (HFpEF)

Phase 2

A Study of Verinurad and Allopurinol in Patients With Chronic Kidney Disease and Hyperuricaemia

CompletedNCT03990363

AstraZenecaChronic Kidney Disease

Start: 2019-07-23End: 2021-11-22Updated: 2023-03-02

Study of Verinurad in Heart Failure With Preserved Ejection Fraction

CompletedNCT04327024

AstraZenecaHeart Failure With Preserved Ejection Fraction (HFpEF)

Start: 2020-05-19End: 2022-04-29Updated: 2023-06-29

Related Papers

Verinurad Plus Allopurinol for Heart Failure With Preserved Ejection Fraction

JAMA Cardiology2024-08-147 citations

Combination Treatment with Verinurad and Allopurinol in CKD

Journal of the American Society of Nephrology2024-02-2024 citations

Pharmacokinetics, pharmacodynamics, and safety of verinurad with and without allopurinol in healthy Asian, Chinese, and non‐Asian participants

Pharmacology Research & Perspectives2022-05-205 citations

Rationale, design, demographics and baseline characteristics of the randomized, controlled, Phase 2b SAPPHIRE study of verinurad plus allopurinol in patients with chronic kidney disease and hyperuricaemia

Nephrology Dialysis Transplantation2021-08-109 citations